$ALZN 90 DAYS STOCK PRICE FORECAST

Stock Price

About the Company

We do not have any company description for Alzamend Neuro Inc at the moment.

Please visit https://alzamend.com/ for more information about the company.

Exchange

NASDAQ

Website

https://alzamend.com/

$M

Total Revenue

3

Employees

$221M

Market Capitalization

-43.33

Price/Earning ratio

Industry Peers

Name Ticker Market Capitalization (USD M) Revenue (USD M) Price/Book Price/Earning Net Margin (%)
Charles River Laboratories Int CRL 22463 3273 9.58 56.69 12.10
Exact Sciences Corp. EXAS 17520 1712 5.22 -19.77 -49.89
PRA Health Sciences Inc PRAH 10739 3333 6.88 50.52 6.40
Syneos Health Inc SYNH 9843 4730 2.99 41.85 4.99
Medpace Holdings Inc MEDP 7069 1028 7.82 40.09 17.02
Vir Biotechnology Inc VIR 6957 183 9.62 -22.93 -162.74
Exelixis Inc EXEL 6651 1157 3.19 71.45 8.13
Twist Bioscience Corp TWST 5722 127 9.83 -43.48 -106.59
Allakos Inc ALLK 5677 10.33 -28.51 None
Sana Biotechnology Inc SANA 4654 5.33 -14.20 None
Recursion Pharmaceuticals Inc RXRX 4504 9 7.04 -36.73 None
Allogene Therapeutics Inc ALLO 3325 38 3.52 -13.87 -621.84
Alx Oncology Holdings Inc ALXO 3112 1 7.75 -26.83 -401.23
Verve Therapeutics Inc VERV 2874 7.09 -29.07 None
Lyell Immunopharma Inc LYEL 2823 8 2.77 -14.58 None
Cortexyme Inc CRTX 2634 18.33 -29.86 None
Instil Bio Inc TIL 2426 0 3.81 -29.39 None
Erasca Inc ERAS 2233 -15.66 -17.65 None
Sorrento Therapeutics Inc SRNE 2206 51 13.03 -6.97 -626.43
Organogenesis Holdings Inc ORGO 2099 433 11.99 27.77 16.17
Castle Biosciences Inc CSTL 1778 78 4.68 -76.55 -28.88
Rubius Therapeutics Inc RUBY 1734 7.11 -10.00 None
Replimune Group Inc REPL 1596 3.18 -17.71 None
Constellation Pharmaceuticals CNST 1564 4.32 -11.18 None
AlloVir Inc ALVR 1511 0 5.17 -12.83 -718.59
Pandion Therapeutics Inc PAND 1501 1069 1.83 -13.34 -10.55
Y-Mabs Therapeutics Inc YMAB 1431 37 6.18 -31.09 -114.04
Monte Rosa Therapeutics Inc GLUE 1383 4.00 -24.01 None
Scholar Rock Holding Corp SRRK 1377 16 6.44 -12.74 -687.82
Caribou Biosciences Inc CRBU 1351 5 -30.71 -26.71 -955.31
Century Therapeutics Inc IPSC 1337 3.01 -19.19 None
National Research Corp NRC 1244 140 15.94 34.16 25.62
Cullinan Oncology Inc CGEM 1162 19 2.53 -21.31 -284.59
Janux Therapeutics Inc JANX 1123 1 2.96 -97.82 -436.67
Graphite Bio Inc GRPH 1085 2.97 -22.01 None
Precigen Inc PGEN 1008 101 7.12 -9.13 -107.45
RAPT Therapeutics Inc RAPT 987 5 5.35 -16.45 7.14
Design Therapeutics Inc DSGN 889 0 2.22 -46.20 -245.44
Sutro Biopharma Inc STRO 838 69 3.00 -9.20 -114.69
Ideaya Biosciences Inc IDYA 833 36 4.29 -31.98 -84.49
Crinetics Pharmaceuticals Inc CRNX 775 0 4.46 -8.74 -447.78
Precision Biosciences Inc DTIL 705 101 7.45 -14.15 -45.88
Imago BioSciences Inc IMGO 681 -8.75 -26.15 None
Acumen Pharmaceuticals Inc ABOS 633 1 -6.19 -6.52 -550.91
Talaris Therapeutics Inc TALS 579 2.18 -17.02 None
Vor Biopharma Inc VOR 568 2.28 -8.68 None
MeiraGTx Holdings plc MGTX 554 19 2.91 -9.58 -325.95
Mirum Pharmaceuticals Inc MIRM 506 11 5.76 -3.33 None
Kezar Life Sciences Inc KZR 496 3.60 -10.35 None
Werewolf Therapeutics Inc HOWL 473 2.57 -2.54 None
Vera Therapeutics Inc VERA 472 5.19 -8.61 None
Aerovate Therapeutics Inc AVTE 464 -22.91 -31.50 None
Rallybio Corp RLYB 428 -6.39 -10.07 None
Evelo Biosciences Inc EVLO 409 7.19 -3.86 None
Magenta Therapeutics Inc MGTA 390 2.25 -5.60 None
Cue Biopharma Inc CUE 387 5 5.59 -8.97 -802.84
Applied Therapeutics Inc APLT 371 14 3.32 -3.25 -19.41
Black Diamond Therapeutics Inc BDTX 342 1.37 -3.25 None
Oyster Point Pharma Inc OYST 341 2.25 -4.27 None
Pieris Pharmaceuticals Inc PIRS 333 24 8.36 -6.88 -203.73
Luna Innovations Inc LUNA 329 101 4.07 142.29 2.46
Biomea Fusion Inc BMEA 318 1.58 -16.89 None
Surface Oncology Inc SURF 305 90 2.18 13.65 18.99
Sensei Biotherapeutics Inc SNSE 301 1.82 -10.57 None
Cabaletta Bio Inc CABA 297 3.05 -7.64 None
Impel NeuroPharma Inc. IMPL 274 5.49 -5.66 None
Sera Prognostics Inc SERA 257 0 -1.79 -10.92 None
INmune Bio Inc INMB 257 0 7.58 -13.19 None
AquaBounty Technologies Inc AQB 243 0 1.38 -11.92 None
Elevation Oncology Inc ELEV 224 1.46 -10.06 None
Alzamend Neuro Inc ALZN 221 130.00 -43.33 None
Compass Therapeutics Inc CMPX 220 7.55 -2.71 None
Gemini Therapeutics Inc GMTX 211 1088 0.23 1.74 11.24
Hookipa Pharma Inc HOOK 202 20 1.60 -3.30 -304.07
Candel Therapeutics Inc CADL 196 0 -5.23 -5.64 None
Nextcure Inc NXTC 196 22 0.73 -2.90 -163.57
Reneo Pharmaceuticals Inc RPHM 192 1.16 -7.00 None
Unity Biotechnology Inc UBX 164 1 2.52 -2.02 None
Tscan Therapeutics Inc TCRX 150 6 -2.50 -4.36 -563.14
IN8bio Inc INAB 133 -6.19 -13.21 None
Exicure Inc XCUR 124 4 3.36 -2.61 -148.49
HCW Biologics Inc HCWB 123 4 -5.58 -19.11 -162.03
Axcella Health Inc AXLA 120 2.56 -2.14 None
Cyclerion Therapeutics Inc CYCN 106 4 2.07 -1.58 None
Scopus Biopharma Inc SCPS 98 234 -49.36 -4.64 80.93
BioVie Inc BIVI 90 37.60 -0.51 None
Eloxx Pharmaceuticals Inc ELOX 88 0 3.98 -1.61 -14.14
CohBar Inc CWBR 67 6.05 -3.97 None
Monopar Therapeutics Inc MNPR 63 2.83 -7.98 None
Rezolute Inc RZLT 57 2.36 -3.18 None
Vaccinex Inc VCNX 55 1 4.15 -1.95 -48.71
Acurx Pharmaceuticals Inc ACXP 46 2.99 -5.72 None
Cytocom Inc CBLI 41 0 5.41 -17.72 -912.16
Cyclo Therapeutics Inc CYTH 41 1 3.94 -1.95 -989.80
Synaptogenix Inc SNPX 41 1.29 -2.70 None
Aridis Pharmaceuticals Inc ARDS 40 0 -4.37 -1.61 -851.00
NanoViricides Inc NNVC 40 1.45 -7.05 None
Unicycive Therapeutics Inc UNCY 39 -9.69 -10.81 None
AgeX Therapeutics Inc AGE 38 2 -4.59 -4.04 -522.77
TransCode Therapeutics Inc RNAZ 29 -6.23 -8.38 None
Kiromic BioPharma Inc KRBP 24 10.81 -1.72 None
Xenetic Biosciences Inc XBIO 19 1 2.30 -1.43 -47.40
Geovax Labs Inc GOVX 19 1 1.52 -13.03 -558.09
Tenax Therapeutics Inc TENX 15 0 22.83 -0.59 -840.64
Neurotrope Inc NTRP 5 29 0.08 0.76 23.48

There Has Been A 1.52% Incline For Alzamend Neuro Inc. (NASDAQ: ALZN). So What’s Next?

22h ago, source: marketingsentinel

Alzamend Neuro Inc. (NASDAQ:ALZN)’s traded shares stood at 2.51 million during the last session. At the close of trading, the ...

Alzamend Neuro Inc. (ALZN) market price of $2.66 offers the impression of an exciting value play

1d ago, source: investchronicle

At the end of the latest market close, Alzamend Neuro Inc. (ALZN) was valued at $2.63. In that particular session, Stock ...

Could The Alzamend Neuro, Inc. (NASDAQ:ALZN) Ownership Structure Tell Us Something Useful?

3d ago, source: Yahoo Finance

Every investor in Alzamend Neuro, Inc. (NASDAQ:ALZN) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership.

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

5d ago, source: Business Wire

TAMPA, Fla.--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of ...

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

5d ago, source: Stockhouse

Company Achieves Milestone of Dosing First Group of Participants in Six-Month Comparative Study with Lithium-Delivering Ionic Cocrystal Oral Treatment Alzamend Neuro, Inc. (Nasdaq: ALZN) ...

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

5d ago, source: wallstreet online

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and ...

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

5d ago, source: Yahoo Finance

September 13, 2021--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of ...

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

5d ago, source: Morningstar%2c Inc.

Alzamend Neuro Announces Initiation of Phase I First ... licenses from the University of South Florida Research Foundation, Inc. Based on preclinical data, AL001 treatment prevents cognitive ...

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

5d ago, source: Benzinga.com

Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially allowing Alzamend ... Foundation, Inc. pursuant to royalty ...

Your Portfolio